Ovarian cancer [DS:H00027] Fallopian tube cancer [DS:H01554] Primary peritoneal cancer [DS:H01665] Ovarian cancer (BRCA mutated) [DS:H00027] Fallopian tube cancer (BRCA mutated) [DS:H01554] Primary peritoneal cancer (BRCA mutated) [DS:H01665]
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK02 Niraparib
D11895 Niraparib tosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Poly (ADP-ribose) Polymerase Inhibitors
Niraparib
D11895 Niraparib tosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11895 Niraparib tosylate (USAN); Niraparib tosilate hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG03120 Niraparib
D11895 Niraparib tosylate
Drug classes [BR:br08332]
Antineoplastic
DG02942 PARP inhibitor
D11895 Niraparib tosylate
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Pentosyltransferases
PARP1
D11895 Niraparib tosylate (USAN) <JP/US>
PARP2
D11895 Niraparib tosylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11895
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11895
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11895
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11895
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11895
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG03120 Niraparib